Lupin Limited has made its debut in the Dow Jones Best-in-Class (DJBIC) Indices 2026, becoming a first-time entrant in both the DJBIC World Index and the DJBIC Emerging Markets Index. The announcement was made on May 19, 2026. The DJBIC World Index ranks top-performing companies globally by strong ESG performance, while the DJBIC Emerging Markets Index highlights sustainability leaders across emerging economies.

Recognition Across Two Prestigious ESG Indices

Lupin's inclusion spans two distinct indices under the Dow Jones Best-in-Class framework. The following table outlines the key parameters of each index:

S&P Global CSA 2025 Score Underpins Inclusion

Lupin's entry into these indices is backed by its performance in the S&P Global Corporate Sustainability Assessment (CSA) 2025, where the company was ranked among the top 1% globally in its industry, achieving an industry-leading score of 91/100. The Dow Jones Best-in-Class Indices select constituents based on leading S&P Global CSA scores, making this prior assessment a direct basis for the current recognition.

Key highlights of Lupin's ESG credentials include:

• Ranked among the top 1% globally in the S&P Global CSA 2025
• Achieved an industry-leading score of 91/100 in the CSA
• First-time inclusion in both the DJBIC World and DJBIC Emerging Markets Indices
• Recognised for performance across Environmental, Social, and Governance (ESG) parameters

Leadership Commentary

Commenting on the development, Ramesh Swaminathan, Executive Director, Global CFO, Head of IT and API Plus SBU, Lupin, stated: "Lupin's inclusion in the Dow Jones Best-in-Class Indices reflects the strength of our governance framework and financial discipline and marks a meaningful advancement in our sustainability journey. This recognition reinforces our long-term value creation agenda—anchored in responsible growth, resilient performance, and our continued commitment to delivering affordable, high-quality medicines to patients worldwide."

Sustainability Commitments Driving the Recognition

Lupin's sustainability agenda encompasses a broad range of initiatives that contributed to its ESG standing. The company's efforts span the following areas:

• Science-based targets for environmental performance
• Environmental stewardship practices
• Quality and safety standards across operations
• Inclusive workplace practices
• Responsible supply chain management

Lupin is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. The company operates 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce of over 24,000 professionals. Its portfolio spans branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across therapy areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.

Lupin Limited inaugurated Atharv Ability, its advanced multidisciplinary neuro-rehabilitation center in Naraina Vihar, Delhi, on May 15, 2026. The facility is dedicated to delivering comprehensive, outcome-driven, specialized care for adults and children with neurological disabilities, with a focus on enhancing mobility, improving quality of life, and supporting long-term recovery. The launch was disclosed pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Expanding Access to Specialized Neuro-Rehabilitation in North India

The Delhi center represents the third Atharv Ability facility under Lupin's neuro-rehabilitation initiative, following the successful launch of centers in Mumbai in 2023 and Hyderabad in 2024. The expansion targets a region where access to integrated, high-quality neuro-rehabilitation services remains limited, aiming to bridge critical treatment gaps for patients across North India.

The center addresses a wide spectrum of neurological conditions, including:

• Stroke
• Traumatic brain injury
• Spinal cord injury
• Parkinson's disease
• Multiple sclerosis
• Pediatric neurological disorders such as cerebral palsy

Advanced Technology and Multidisciplinary Care

Atharv Ability integrates clinical expertise with cutting-edge technology to deliver personalized care programs. The key features of the Delhi facility are outlined below:

Leadership Commentary

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin, said, "As advances in neurological treatment continue to improve outcomes, rehabilitation offers a powerful opportunity to restore independence and enable meaningful recovery. Atharv Ability embodies this belief that healthcare must extend beyond treatment to sustained recovery, with personalized, patient-focused care. This expansion underscores our belief that high-quality neuro-rehabilitation must be accessible, affordable, and standardized across India."

About Lupin Limited

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin maintains a strong presence in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. The company operates 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce of over 24,000 professionals. Lupin's subsidiaries — Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions — further its commitment to improving patient health outcomes.